Valuation : ReShape Lifesciences

Market Cap 15.23M 13.14M 12.36M 11.26M 21.17M 1.45B 21.29M 146M 56.86M 735M 57.18M 55.94M 2.44B P/E 2026 *
-3.08x
P/E 2027 * -2.37x
Enterprise Value 15.23M 13.14M 12.36M 11.26M 21.17M 1.45B 21.29M 146M 56.86M 735M 57.18M 55.94M 2.44B EV / Sales 2026 *
102x
EV / Sales 2027 * 60.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 129K 122K 111K 209K 14.24M 210K 1.44M 560K 7.24M 563K 551K 24.01M 250K 216K 203K 185K 348K 23.73M 349K 2.4M 933K 12.07M 939K 918K 40.02M
Net income -4.89M -4.22M -3.97M -3.61M -6.8M -464M -6.83M -46.91M -18.26M -236M -18.36M -17.96M -783M -7.77M -6.7M -6.3M -5.74M -10.8M -737M -10.86M -74.52M -29.01M -375M -29.17M -28.54M -1.24B
Net Debt - -
Logo ReShape Lifesciences
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-